A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
This study is testing a new type of immune cell therapy called CNDO-109-activated natural killer cells for people with a high-risk type of blood cancer called acute myeloid leukemia. Researchers want to see if giving these specialized immune cells is safe and helps prevent the cancer from coming back.
You might be able to join if you are an adult with acute myeloid leukemia who is currently in remission and considered high-risk for the cancer returning. Participants must not be candidates for a stem cell transplant and must have a healthy family member who can donate immune cells.
Before receiving the treatment, you will go through a preparatory chemotherapy regimen to get your body ready. Afterward, you will receive infusions of the specialized donor immune cells at increasing dose levels so doctors can monitor safety.
This study takes place at medical centers in locations such as Tampa, Florida, Minneapolis, Minnesota, and St. Louis, Missouri. The current status of the study is unknown, so you should check with the study team for the latest updates on enrollment.
- 1Tests a specialized immune cell therapy to help prevent leukemia from returning
- 2Designed for adults in remission who cannot have a stem cell transplant
- 3Involves receiving immune cells from a family member after preparatory chemotherapy
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.